Factors influencing the therapeutic effect of roxadustat in hemodialysis patients with erythropoietin hyporesponsive renal anemia
Objective To analyze the influencing factors of the therapeutic effect of rosacetam on hemodialysis patients with erythropoietin hyporesponsive renal anemia.Methods A retrospective analysis was conducted on 113 patients with erythropoietin hyporesponsive renal anemia undergoing hemodialysis who were treated with roxadustat at the Second Hospital of Lishui from January 2021 to December 2023.The patients were divided into two groups based on whether their hemoglobin(Hb)levels reached the target value after 12 weeks of treatment:the Hb standard group(71 cases)and the Hb non-standard group(42 cases).Clinical data from the two groups were collected and compared,and a binary Logistic regression model was used to further analyze the factors influencing the therapeutic effect of Roxadustat in hemodialysis patients with erythropoietin hyporesponsive renal anemia.Results The dialysis duration in the Hb standard group was shorter than that in the Hb non-standard group,while the baseline Hb and estimated glomerular filtration rate(eGFR)levels were higher than those in the Hb non-standard group.In addition,the baseline blood platelet-to-lymphocyte ratio(PLR)level was lower in the Hb target-reaching group compared to the Hb non-standard group,and all these differences were statistically significant(P＜0.05).The results of the multivariate binary Logistic regression model showed that dialysis duration,baseline Hb,and PLR were independent factors influencing whether Hb reached the standard in hemodialysis patients with erythropoietin hyporesponsive renal anemia treated with Roxadustat(P＜0.05).Conclusion In hemodialysis patients with erythropoietin hyporesponsive renal anemia,those with shorter dialysis duration,higher baseline Hb levels,and lower PLR levels are more likely to achieve the target Hb level after treatment with roxadustat.Therefore,clinical attention should be paid to the influence of these factors on the efficacy of roxadustat in such patients.
万方数据
维普
